Peptide · Melanocortin receptor agonist
Bremelanotide (PT-141)
A melanocortin receptor agonist peptide, authorised for acquired, generalised hypoactive sexual desire disorder in premenopausal women.
Approved medicineAuthorised by a regulator, available on prescription.
- Legal status · US
- Approved medicine
- Evidence in people
- Molecule
- 7 amino acids
- In sport
- Not named on the WADA list
- Status checked
Regulatory status · United States
This describes the position in the United States. Rules in Canada differ; an approved peptide medicine there is in its national register.
An approved prescription medicine under the brand name Vyleesi. "PT-141" sold as a research chemical is not that product.
Authorised products
| Brand | Authorised for | How it is given | First US approval |
|---|---|---|---|
| Vyleesi | Hypoactive sexual desire disorder in premenopausal women | Injection, as needed | 2019 |
Doses, warnings and who should not use it are on each product’s official label, linked from its page.
Every authorised product in CanadaWhat changed, and when
US approval, as Vyleesi.
What to be careful about
The approved product is an autoinjector with a label that sets limits on how often it may be used and warns about blood pressure. A research vial comes with none of that.
Sources
Regulatory positions change. This page states the date it describes, and nothing on it is legal or medical advice.